CellCentric secures $220 million Series D to advance multiple myeloma oral therapy
read at Endpoints ↗DealPositive
CellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round.
The capital will be used to complete development and prepare for commercialization of its oral drug candidate aimed at patients with multiple myeloma who have exhausted other treatment options.
The sizable raise underscores investor confidence in the company's approach and provides resources to move the therapy toward regulatory submission and market launch.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “CellCentric raises $220M to get multiple myeloma pill to market”
read at Endpoints ↗85 words · retrieved May 6
comments(0)
5-min edit window · permanent after that